Pipeline Overview

Innovative Drugs Designed to Improve Patients’ Lives

Our pipeline includes internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies, solid tumors, autoimmune diseases, and viral diseases. It comprises both Chimeric Targeting Molecules (CTMs) for targeted protein degradation to eliminate disease causing proteins and Ligase Inhibitors that target key control elements in immune regulation. Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of CTMs against a set of unique targets.

Drug Candidate	Target (Delivery)	Therapeutic Area	Discovery	IND enabling	Phase 1	Phase 2	Phase 3
Clinical Pipeline
NX-2127 Degrader	BTK + IMiD Activity (Oral)	B-cell malignancies
NX-5948 Degrader	BTK (Oral)	B-cell malignancies and autoimmune disease
NX-1607 Inhibitor	CBL-B (Oral)	Immuno-oncology
DeTIL-0255 Cell Therapy	Adoptive cell therapy with ex vivo CBL-B inhibition	Gynecologic malignancies
Drug Candidate	Target (Delivery)	Therapeutic Area	Discovery	IND enabling	Phase 1	Phase 2	Phase 3
Discovery Pipeline
Wholly Owned	Multiple targets*	Undisclosed
Gilead Sciences	5 targets	Undisclosed
Sanofi	5 targets	Undisclosed

Candidate / Target	Phase
Clinical Pipeline
NX-2127 Degrader BTK + IMiD Activity (Oral)	Phase 1
NX-5948 Degrader BTK (Oral)	Phase 1
NX-1607 Inhibitor CBL-B (Oral)	Phase 1
DeTIL-0255 Cell Therapy Adoptive cell therapy with ex vivo CBL-B inhibition	Phase 1
Discovery Pipeline
Wholly Owned Multiple targets*	Discovery
Gilead Sciences 5 targets	Discovery
Sanofi 5 targets	Discovery

Degraders and inhibitors of multiple targets including E3 ligases, T cell kinase, hematology & oncology drivers, and viral proteins